Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine X2,000mg/m2, p.o.(day1-14) to be repeated every 3 weeks
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2619370 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA